Aduro Appoints Gregory W. Schafer as Chief Operating Officer
Aduro BioTech Inc.Posted on:23 Jul 13
Aduro BioTech Inc. announces today the appointment of Gregory W. Schafer as chief operating officer (COO). As COO Mr. Schafer will lead the company’s corporate strategy and operations.
“We are delighted to bring Greg into Aduro at this exciting time as we move into later-stage clinical trials with our lead program for pancreatic cancer” said Stephen Isaacs chairman and chief executive officer of Aduro. “We look forward to leveraging Greg’s extensive experience in the industry particularly as it relates to planning and supporting the growing and more complex operations of a biotechnology company progressing towards commercialization.”
Mr. Schafer brings more than 23 years of broad operational financial and strategic leadership expertise to Aduro and has raised over $650 million in public and private transactions to fund biotechnology product development and commercialization activities. Most recently he served as chief financial officer of Jennerex Inc. for 3 years where he was responsible for finance accounting planning investor relations and treasury functions. Prior to Jennerex he served as chief financial officer of Onyx Pharmaceuticals Inc. where he was responsible for finance accounting risk management and strategic and operational planning. Before joining Onyx he served as chief financial officer and vice president of finance for Cerus Corporation where he worked together with then-chief executive officer Stephen Isaacs to transition the company from early-stage development to product approval. Prior to Cerus Mr. Schafer worked as a management consultant for Deloitte & Touche LLP and as an engineer specializing in biologics manufacturing. Mr. Schafer also serves on the board of directors for Nile Therapeutics a public biotechnology company. He received his MBA from the Anderson Graduate School of Management at the University of California Los Angeles and a BSE in mechanical engineering from the University of Pennsylvania.
About Aduro BioTech Inc.
Aduro BioTech Inc. is a clinical-stage immunotherapy company located in Berkeley California. Aduro has completed enrollment in a randomized controlled Phase 2 clinical trial in patients with metastatic pancreatic cancer and is conducting a Phase 1B trial in patients with malignant pleural mesothelioma. In addition the company’s preclinical pipeline includes programs in glioblastoma prostate cancer melanoma malaria HBV and tularemia.
Business Wire
http://www.businesswire.com/
Last updated on: 23/07/2013 14:00:05
0 comments:
Post a Comment